Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck antibiotic approved in US
This approval was based upon the results of a large comparative trial for surgical site infection (SSI) in patients who have had colorectal surgery. “Given the high incidence
This approval was based upon the results of a large comparative trial for surgical site infection (SSI) in patients who have had colorectal surgery. “Given the high incidence
The transaction saw GSK purchase all outstanding CNS shares for approximately $566 million. According to GSK, CNS reported a 20% increase in sales in fiscal 2006 over the
However, the drugs label will also contain an unexpected warning that it can cause side effects such as heart problems. Invega contains paliperidone, the active ingredient derived from
The Navy and the FDA communicated following a meeting of the Blood Products Advisory Committee (BPAC). The BPAC voted against proceeding with the proposed phase IIb/III trial. Committee
The study compares two doses of Androxal, 12.5mg and 25mg, to both placebo and open-label Androgel, Solvay’s testosterone replacement cream. Repros said that Androxal, which is an oral
Post-operative ileus (POI) is a temporary impairment of gastrointestinal (GI) function and a common response to abdominal surgical procedures. The companies believe that because many postoperative patients cannot
Reverse genetics is a method by which viruses such as influenza can be generated entirely from segments of DNA. MedImmune believes this deal is important as the technology
Labopharm said its response includes additional analysis of its existing data. The company suggested that it had addressed all of the matters raised by the FDA. Labopharm has
The phase II clinical trial is designed to determine the efficacy and safety of eight different dose and formulation profiles of NG2-73 compared to placebo. The primary endpoint
The study will investigate the efficacy of atacicept in patients with an inadequate response to prior treatment with TNF inhibitors. The efficacy of atacicept will be evaluated according